| Metric | Value ($ M) | vs Q2 FY26 |
|---|---|---|
| Revenue | 24.55 | 8.8% |
| Total Income | 24.55 | 8.8% |
| Expenditure | 59.32 | 9.2% |
| PBT | -34.13 | 4.2% |
| Net Profit | -34.17 | 4.2% |
| OPM | — | |
| NPM | — | |
| EPS | -0.61 | 4.7% |
Kestra Medical Technologies Reports Q3 FY26 Revenue Up 63%
04 May 2026 · 4 May, 12:27 am
Summary
Kestra Medical Technologies reported financial results for the third quarter fiscal 2026, which ended January 31, 2026. The company generated revenue of $24.6 million, an increase of 63% compared to the prior year period. Gross margin expanded to 52.6% compared to 43.4% in the prior year period. Kestra is increasing its FY26 revenue guidance to $93 million, which would represent growth of 55% compared to FY25.
Key Highlights
- 1
Kestra Medical Technologies generated revenue of $24.6 million in Q3 FY26, an increase of 63% compared to the prior year period.
- 2
The company expanded gross margin to 52.6% in Q3 FY26 compared to 43.4% in the prior year period.
- 3
Kestra increased FY26 revenue guidance to $93 million, representing growth of 55% compared to FY25.
- 4
5,462 prescriptions were written for the ASSURE® system, an increase of 58% compared to the prior year period.
- 5
GAAP net loss and comprehensive loss was $34.2 million compared to GAAP net loss and comprehensive loss of $21.8 million in the prior year period.
Management Comments
Brian Webster
Kestra delivered another strong quarter of financial performance, generating revenue growth of 63% while expanding gross margin to over 52%. We also continued to execute on several key operational objectives, including rapid growth of the commercial organization, release of compelling primary results from our FDA post-approval study, fortification of our balance sheet with an equity offering, and entrance into a strategic collaboration with Biobeat Technologies. As we progress on our journey to category leadership, our team remains focused on growing the wearable defibrillator market and executing on our commitments to patients and their prescribers.”
Informational and educational content only. Not investment advice.